Navigation Links
Mice point to a therapy for Charcot-Marie-Tooth disease
Date:8/2/2011

use neurons. The mouse model develops motor symptoms, muscle atrophy and weakness, foot deformities and steppage gait, all very similar to symptoms observed in affected individuals. Furthermore, the mice develop sensory problems that also occur in CMT patients. Pathological examination of the nerves of the CMT mice shows that the contact between the nerve endings and muscles is disturbed.

Axonal transport deficits

The CMT mice provide the unique possibility to isolate and culture affected nerve cells, making it possible to investigate what exactly goes wrong in the sick nerves. It was discovered that the transport of mitochondria (the cellular power plants) within the axons is severely disturbed in the neurons from symptomatic CMT mice, most likely because the tracks along which the mitochondria are transported (microtubules) are damaged. This could lead to a chronic lack of sufficient mitochondria and other transported cargoes at the nerve endings, causing the nerves to degenerate.

Possible treatment of CMT by HDAC6 inhibitors

These new insights also open possibilities for treatment, because the mitochondrial transport in nerve fibers is known to be affected by tubulin deacetylation, a posttranslational modification of the building blocks of microtubules catalyzed by histone deacetylase 6 (HDAC6). Inhibitors of HDAC6 do not only reverse the axonal transport deficits in vitro, treatment of the CMT mice with HDAC6 inhibitors also halts the damage to the nerves and even succeeds in reversing the symptoms, most likely by muscle reinnervation. The most specific therapeutic molecule used in this study (Tubastatin A) was made by Alan Kozikowski from the University of Illinois at Chicago (USA).

Mouse medicine is not the same as human medicine

There is still a long way to go before these drugs will become available for patients. Many experimental drugs even those that are successful in animal models fail dur
'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
32-477-697-668
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UCI study points to new means of overcoming antiviral resistance in influenza
2. GEN point of view article questions reported costs of drug R&D
3. Yale researchers pinpoint reasons for dramatic rise in cesarean births
4. Anaphore Appoints Paul A. Grayson President and CEO
5. Salk scientist Joseph Ecker, appointed as HHMI-GBMF Investigator
6. CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator
7. TGen Drug Development partners with Imaging Endpoints for comprehensive clinical trial services
8. Scientists use super microscope to pinpoint body’s immunity switch
9. Rices origins point to China, genome researchers conclude
10. Human rules may determine environmental tipping points
11. Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... nutrients that can negatively impact aquatic ecosystems and human ... streams and aquifers across the Nation since the early ... U.S. Geological Survey. "This USGS report provides the ... phosphorus in our streams and groundwater," said Marcia McNutt, ...
... since victory gardens helped World War II era Americans ... gardens been as necessary and popular as they are ... of the produce grown there becomes increasingly important. ... and vegetables for family consumption and planning ahead for ...
... report by the International Osteoporosis Foundation (IOF) show alarming ... in the Russian Federation and many other countries in ... press conference in St. Petersburg at the IOF Summit ... Osteoporosis, a disease of the bone which leaves ...
Cached Biology News:Elevated nitrogen and phosphorus still widespread in much of the nation's streams and groundwater 2Elevated nitrogen and phosphorus still widespread in much of the nation's streams and groundwater 3Urban gardeners beware: There may be lead in your soil and food 2High death and disability rates due to fractures in Russia, Central Asia and Eastern Europe 2
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... June 2, 2015   Y-Prime, Inc ., ... BIO Exhibition 2015 in Philadelphia ... largest biotechnology gathering, allows influential decision makers from ... they can evaluate emerging technologies such as YPrime. ... in the design, implementation and management of Interactive ...
(Date:6/2/2015)... June 2, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that Dr. Pamela Pavco ... at the 23 rd World Congress ... will include in-depth presentations by world-class clinicians ...
(Date:6/2/2015)... , June 2, 2015 ... the global antibiotic resistance problem  MGB ... class of anti-infectives, to address the major global ... has developed a stable intravenous (IV) formulation of MGB-BP-3, ... resistant Gram-positive hospital-acquired infections.  The intravenous formulation ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3
... CALGARY, March 13 /PRNewswire-FirstCall/ - SemBioSys Genetics ... portfolio of therapeutic,proteins for metabolic and cardiovascular ... European patent EP0986309(B1) entitled "Uses of Oil,Bodies". ... which has exclusively,licensed commercial rights associated with ...
... Innocoll, Inc., a,privately-held biopharmaceutical company, announced that ... 2 clinical trials sponsored by its wholly ... SURGICAL IMPLANT for the management of post-operative ... IMPLANT is a biodegradable and fully,bioresorbable matrix ...
... Support Commencement of Longer-term Phase 2 Switching ... Amicus Therapeutics, a,biopharmaceutical company developing small-molecule, orally ... genetic diseases,announced today that the Company will ... study of Plicera(TM) (isofagomine tartrate) for Gaucher ...
Cached Biology Technology:SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office 2SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 2Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 3Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 4
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
Biology Products: